Welcome to our dedicated page for MedTech Acquisition Corporation news (Ticker: MTACW), a resource for investors and traders seeking the latest updates and insights on MedTech Acquisition Corporation stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MedTech Acquisition Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MedTech Acquisition Corporation's position in the market.
MedTech Acquisition Corporation (NASDAQ: MTAC) has postponed its special meeting of stockholders to December 12, 2022, to secure more votes for the Extension Amendment. This amendment seeks to extend the deadline for completing a business combination from December 22, 2022, to June 22, 2023. The company is currently working to finalize a merger with TriSalus Life Sciences, Inc.. Stockholders as of the record date, October 24, 2022, can still vote regardless of share sales.
Approval of the merger is critical for the company’s future as it plans to rebrand as TriSalus Life Sciences upon completion.
MedTech Acquisition Corporation (Nasdaq: MTACU) announced it received a notice from Nasdaq due to the late filing of its Quarterly Report on Form 10-Q for Q1 2021. The company failed to meet the deadline because of accounting issues regarding outstanding warrants. Nasdaq has granted the company 60 days, until July 26, 2021, to submit a compliance plan. If accepted, an extension of up to 180 days may be granted. Failure to comply could lead to suspension or delisting, negatively impacting the trading of its units, warrants, and common stock.
MedTech Acquisition Corporation (Nasdaq:MTACU) announced that from February 8, 2021, holders of its 25 million initial public offering units can trade shares of Class A common stock and warrants separately on Nasdaq. The shares will trade under the symbols 'MTAC' for common stock and 'MTACW' for warrants, while the undivided units will continue trading as 'MTACU.' The registration statement for these securities was declared effective by the SEC on December 17, 2020. MedTech Acquisition aims to focus on merging with businesses in the medical technology sector.
MedTech Acquisition Corporation closed its initial public offering of 25,000,000 units, including 3,000,000 units from the underwriters’ over-allotment, at $10.00 per unit, totaling $250,000,000 in gross proceeds. The units commenced trading on Nasdaq under the symbol MTACU on December 18, 2020. Each unit comprises one share of Class A common stock and one-third of a redeemable warrant. Funds raised are placed in a trust account for future business combinations, primarily focusing on the medical technology sector.
MedTech Acquisition Corporation announced the pricing of its initial public offering (IPO) of 22,000,000 units at $10.00 each, scheduled to trade on Nasdaq under the symbol MTACU starting December 18, 2020. Each unit consists of one share of Class A common stock and one-third of a redeemable warrant, which can be exercised at $11.50 per share. The company, a blank check entity, aims to pursue a business combination in the medical technology sector. Raymond James & Associates is the sole book-running manager for the offering, with a 45-day option for underwriters for an additional 3,300,000 units.
